Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Relay Therapeutics IncfiledCriticalRelay Therapeutics Inc
Publication of AR124860A1publicationCriticalpatent/AR124860A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente descripción se refiere a compuestos novedosos y composiciones farmacéuticas de estos, y métodos para inhibir la actividad de las enzimas CDK con los compuestos y las composiciones de la descripción. Además, la presente descripción se refiere, de modo no taxativo, métodos para tratar trastornos asociados con la señalización de CDK con los compuestos y las composiciones de la descripción.The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods of inhibiting the activity of CDK enzymes with the compounds and compositions of the disclosure. In addition, the present disclosure relates, but is not limited to, to methods of treating disorders associated with CDK signaling with the compounds and compositions of the disclosure.
ARP220100279A2021-02-122022-02-11
CDK INHIBITORS AND METHODS OF USE THEREOF
AR124860A1
(en)
Crystal forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1, 2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide